# Clinical Trial to Assess the Safety and Pharmacokinetics of HUG116 Tablet and Viread® Tablet in Healthy Male Volunteers

> **NCT02902523** · PHASE1 · COMPLETED · sponsor: **Huons Co., Ltd.** · enrollment: 50 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Viread® tablet 300mg
- **DRUG:** HUG116 tablet 245mg

## Key facts

- **NCT ID:** NCT02902523
- **Lead sponsor:** Huons Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2016-10
- **Final completion:** 2016-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02902523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02902523, "Clinical Trial to Assess the Safety and Pharmacokinetics of HUG116 Tablet and Viread® Tablet in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02902523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*